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A B S T R A C T
Background: Till date, China has not issued industry standards for reference intervals (RIs) of pediatric blood
coagulation indices. Here, we evaluated changes in the coagulation indices in the venous blood of healthy
children aged 29 days to 12 years derived using the ACL Top 700 system and established appropriate RIs.
Methods: We analyzed venous blood from 1770 healthy children for five coagulation indices. RIs were estab-
lished according to the Clinical and Laboratory Standards Institute C28-A3c guideline.
Results: The coagulation indices were grouped by age. For prothrombin time (PT) and international normal-
ization ratio (INR), the RIs of infants and toddlers were identical; preschool children had the same RI as school-
age children. Pediatric RIs for PT and INR were slightly lower than those for adults. The RIs of activated partial
thromboplastin time (APTT), thrombin time (TT), and fibrinogen (FIB) in childhood were divided into two
groups by age (1 month to 1 year and 1–12 years). The RI of APTT in infants was the widest; the overall level of
FIB in infants was the lowest; children's APTT and FIB RIs were lower than those of adults. The pattern of TT
values and RI trends in childhood were similar to those of APTT.
Conclusions: There were minor changes in the RIs of coagulation indices for children. The RIs of PT, INR, APTT,
TT, and FIB must be grouped by age. The RIs of coagulation indices for children were different from those for
adults; therefore, establishing separate RIs for children is necessary.
1. Introduction
Coagulation function screening is often required in clinical practice,
such as during preoperative preparation and for treating infectious and
hemorrhagic diseases [1–3]. The accuracy of coagulation tests has
greatly improved with the development of testing technology and
widespread use of the coagulation analyzer. The clinical interpretation
of coagulation test results largely depends on established reference in-
tervals (RIs) derived from clinical studies in healthy populations. Most
countries or regions do not have RI initiatives and sufficient resources
to establish RIs for their local population. This remains a critical gap in
the field. Coagulation test results are known to depend on the analyzers
/ reagents used. Therefore, laboratories should technically establish
their own RIs according to the guideline. Children cannot be merely
considered miniature adults, at least for the purpose of hemostasis [4].
Researchers in some countries have established RIs for coagulation
parameters in local children. For instance in France, ACL analyzers and
supporting reagents were used to define the age-specific RIs for coa-
gulation parameters in pediatric populations [5]; Austrian researchers
used Siemens and Stago analyzers and supporting reagents to set up
dynamic RIs for coagulation parameters from infancy to adolescence
[6]. It appears that laboratories using the same analyzers and reagents
may share RIs; however, the applicability to different ethnic groups
needs to be verified. At present, there is no uniform industry standard in
China for coagulation screening indicators for children; the RIs of
coagulation indices used in different children's hospitals are either
those recommended by the “National Guide to Clinical Laboratory
Procedures in China” [7], those provided by manufacturers of clinical
laboratory analysis systems, or those that are self-established and va-
lidated by each hospital laboratory. However, differences caused by
race, age, and sex and differences in methodology, detection systems,
and reagents may affect the applicability of selected RIs [5,6].
In this study, we screened venous blood samples from apparently
healthy children (aged > 28 days to 12 years old) in southwest Fujian,
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China, for coagulation indices according to the C28-A3c guidelines [8]
and established RIs of blood coagulation indices suitable for local
children.
2. Materials and Methods
2.1. Study population
In this present study, the coagulation tests of the study subjects were
obtained retrospectively, and laboratory information system results
were analyzed. Apparently healthy children were selected as study
subjects. These children were either diagnosed with a finger or toe
deformity or underwent preparations for elective hernia surgery at the
Department of Pediatric Surgery of the Women and Children's Hospital,
School of Medicine, Xiamen University. All study subjects were from
the Xiamen, Quanzhou, Zhangzhou, or Longyan areas. All study sub-
jects underwent detailed physical examinations and disease history
consultation during hospitalization. The exclusion criteria were as fol-
lows: positive history of heart, liver, kidney, hematological diseases and
allergic or autoimmune diseases, acute and/or chronic infections within
1 month prior to enrolment, intake of any drugs and/or supplements
within the 2 weeks prior to enrolment, height and/or weight out of
corresponding ranges (mean value plus or minus two standard devia-
tions for reference population of same age and sex), and the presence of
any secondary sexual characteristics [9]. A total of 1770 children
aged > 28 days to 12 years [as the numbers of selected neonates
(≤28 days) and children aged ≥ 12 years were too small, these age
groups were excluded] tested between January 1, 2017 and May 31,
2019 were selected; this included 416 infants (≥29 days–<1 year of
age, Ag1), 626 toddlers (≥1–<3 years of age, Ag2), 440 preschool-age
children (≥3–<6 years of age, Ag3), and 288 school-age children
(≥6–<12 years of age, Ag4). The study design was approved by the
hospital Institutional Review Board Committee; the Declaration of
Helsinki was adhered to throughout the study.
2.2. Sample collection and processing
Venous blood was collected using a 21–23 gauge needle into evac-
uated glass tubes (Fuzhou Chang Geng Medical Devices Co. Ltd, China)
containing 0.109 M sodium citrate (1 vol/9 vol) according to interna-
tional recommendations [10]. Each evacuated tube was filled with
exactly 2 ml of anticoagulated blood, which was gently inverted back
Fig. 1. Scatterplots of the five coagulation indices. Note: M, male; F, female.
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and forth several times after blood collection. Plasma was obtained by
centrifugation at 3000g and +20 °C for 10 min, and the coagulation test
was completed within 1 h after blood collection.
2.3. Laboratory assays
An automatic coagulation analyzer (ACL TOP 700, Instrumentation
Laboratory Company, USA) and auxiliary reagents, calibration plasma,
and quality control materials were used. Sample testing was performed
by an ISO 15189 accredited laboratory in strict accordance with oper-
ating instructions. The following coagulation indices were assessed:
prothrombin time (PT), international normalization ratio (INR), acti-
vated partial thromboplastin time (APTT), thrombin time (TT), and
fibrinogen (FIB). The following reagents were used: PT Reagent, APPT
Reagent, TT Reagent, Fibrinogen Reagent, Calibration plasma, normal
control, low abnormal control, and high abnormal control; all were
used within their respective expiration dates.
2.4. Statistical analysis and determination of RIs
All data were analyzed according to the CLSI C28-A3c guidelines
[8]. Statistical analysis was performed using SPSS 22.0 software (IBM,
Armonk, New York, United States). First, we inspected data using
boxplots and removed outliers. Second, we statistically confirmed the
age and sex grouping using the Harris and Boyd method [11]; when
Z > Z*, partitioning was considered necessary (Note: s1 is the standard
deviation of the first group; s2 is the standard deviation of the second
group;
−
x1 is the mean of the first group;
−
x2 is the mean of the second
group; n1 is the number of subjects in the first group; and n2 is the
number of subjects in the second group, Z= −
+
− −
x x1 2
s1
2
n1
s2
2
n2
; Z*= +3 n n
240
1 2 ).
Third, the data in each partition were transformed by the Box–Cox
transformation method, and Q-Q plots were used to assess the nor-
mality of each partition. We used the Tukey and adjusted Tukey tests
twice to remove outliers in normally distributed and skewed partitions,
respectively. Finally, we used the non-parametric rank method to cal-
culate the RI for all partitions as all groups included > 120 partici-
pants. We also calculated 90% confidence intervals (CIs) for the upper
and lower limits of each RI with the weighted data.
3. Results
A total of 1770 subjects were included in the present study. Among
the five indices, PT, APTT, TT, and FIB were directly measured by the
instrument; INR was obtained from instrument calculation. Scatterplots
of the five coagulation indices are shown in Fig. 1.
According to scatterplots of the parameters, we divided the children
into the following groups: infants (≥29 days–<1 year of age, Ag1);
toddlers (≥1–<3 years of age, Ag2), preschool-age children (≥3–<6
years of age, Ag3), and school-age children (≥6–<12 years of age,
Ag4). Age and sex partitions of each coagulation parameter were de-
termined using the Harris and Boyd method. See Tables 1 and 2 for
details.
As depicted in Table 1, none of the five coagulation indices needed
sex-specific partitioning. For male–female comparisons in each age
Table 1
The partitions of five coagulation indices by sex groups.
Indices Group Sex Number Mean Standard deviation Z Z*
PT, sec Ag1 Male 247 11.17 0.81 1.52 3.95
Female 169 11.29 0.78
Ag2 Male 391 11.45 0.73 1.07 4.85
Female 235 11.51 0.65
Ag3 Male 238 11.71 0.70 1.03 4.06
Female 202 11.78 0.72
Ag4 Male 139 11.77 0.70 1.96 3.29
Female 149 11.93 0.69
INR Ag1 Male 247 1.03 0.074 1.39 3.95
Female 169 1.04 0.071
Ag2 Male 391 1.06 0.066 1.96 4.85
Female 235 1.07 0.059
Ag3 Male 238 1.08 0.064 1.61 4.06
Female 202 1.09 0.065
Ag4 Male 139 1.09 0.063 1.35 3.29
Female 149 1.10 0.062
APTT, sec Ag1 Male 247 35.62 4.26 2.14 3.95
Female 169 36.68 5.38
Ag2 Male 391 33.95 4.02 0.96 4.85
Female 235 34.25 3.63
Ag3 Male 238 34.43 4.04 0.44 4.06
Female 202 34.59 3.66
Ag4 Male 139 34.39 3.38 0.03 3.29
Female 149 34.38 3.24
TT, sec Ag1 Male 247 18.28 1.62 0.50 3.95
Female 169 18.37 1.91
Ag2 Male 391 16.92 1.31 1.52 4.85
Female 235 16.77 1.13
Ag3 Male 238 16.63 1.28 1.80 4.06
Female 202 16.42 1.16
Ag4 Male 139 16.43 1.15 1.98 3.29
Female 149 16.17 1.07
FIB, g/L Ag1 Male 247 2.12 0.51 0.94 3.95
Female 169 2.07 0.54
Ag2 Male 391 2.40 0.46 1.39 4.85
Female 235 2.45 0.42
Ag3 Male 238 2.50 0.50 1.50 4.06
Female 202 2.57 0.49
Ag4 Male 139 2.55 0.50 1.08 3.29
Female 149 2.61 0.44
Note: Ag1, infant (≥29 days–<1 year); Ag2, toddler (≥1 year–<3 years);
Ag3, preschool-age children (≥3 years–<6 years); Ag4, school-age children
(≥6 year–<12 years).
Table 2
The partitions of five coagulation indices by age groups.
Indices Program Group Number Mean Standard
deviation
Z Z*
PT, sec Ag1 VS Ag2 Ag1 416 11.20 0.80 5.42 6.25
Ag2 626 11.46 0.71
Ag2 VS Ag3 Ag2 626 11.46 0.71 6.36 6.32
Ag3 440 11.74 0.71
Ag3 VS Ag4 Ag3 440 11.74 0.71 2.45 5.22
Ag4 288 11.87 0.70
INR Ag1 VS Ag2 Ag1 416 1.04 0.07 4.76 6.25
Ag2 626 1.06 0.06
Ag2 VS Ag3 Ag2 626 1.06 0.06 8.11 6.32
Ag3 440 1.09 0.06
Ag3 VS Ag4 Ag3 440 1.09 0.06 2.22 5.22
Ag4 288 1.10 0.06
APTT, sec Ag1 VS Ag2 Ag1 416 35.92 4.63 6.92 6.25
Ag2 626 34.03 3.93
Ag2 VS Ag3 Ag2 626 34.03 3.93 1.96 6.32
Ag3 440 34.50 3.87
Ag3 VS Ag4 Ag3 440 34.50 3.87 0.41 5.22
Ag4 288 34.39 3.28
TT, sec Ag1 VS Ag2 Ag2 416 18.30 1.71 14.49 6.25
Ag3 626 16.88 1.27
Ag2 VS Ag3 Ag3 626 16.88 1.27 4.36 6.32
Ag4 440 16.54 1.23
Ag3 VS Ag4 Ag4 440 16.54 1.23 3.08 5.22
Ag5 288 16.27 1.11
FIB, g/L Ag1 VS Ag2 Ag2 416 2.11 0.52 7.95 6.25
Ag3 626 2.42 0.45
Ag2 VS Ag3 Ag3 626 2.42 0.45 3.69 6.32
Ag4 440 2.53 0.50
Ag3 VS Ag4 Ag4 440 2.53 0.50 1.64 5.22
Ag5 288 2.59 0.47
Note: Ag1, infant (≥29 days–<1 year); Ag2, toddler (≥1 year–<3 years);
Ag3, preschool-age children (≥3 years–<6 years); Ag4, school-age children
(≥6 years–<12 years).
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group, the Z value was less than the Z* value. As presented in Table 2,
all five of the coagulation indices required partitioning by age, as the
indices indicated that the Z value was greater than the Z* value among
different age groups.
We used the non-parametric rank method to calculate the RIs for all
partitions and then calculated 90% CIs for the upper and lower limits of
each RI with the weighted data. The RIs of the five coagulation indices
are presented in Table 3.
4. Discussion
Coagulation screening (PT, INR, APTT, TT, and FIB) is necessary for
preoperative preparation, anticoagulation therapy, thrombolytic
therapy, infectious disease evaluation, etc. The coagulation system in
childhood is immature and developing [12]. At the same time, the
plasma concentrations of most pro- and anticoagulant proteins in
childhood are lower than those in adults [13]. As a result, the RIs for
coagulation indices in children are different from those in adults. On
the basis of these factors, this study retrospectively analyzed the results
of venous blood coagulation screening in apparently healthy children in
southwest Fujian province, China, and established RIs for coagulation
indices suitable for local pediatric populations.
In this study, we observed that each coagulation index measured at
the same age range (> 28 days to 12 years) did not need sex-specific
RIs; however, all indices measured required grouping by age, as re-
ported by Toulon et al. [5]. We found that the test results of PT were
consistent throughout childhood; however, the Harris and Boyd method
[11] suggested establishing RIs in two age groups, namely, 1 month to
3 years and 3–12 years. According to Weidhofer’s et al., there is little
difference in the RIs of PT between children and adults [6]; our study
showed similar results. In 1985, the International Council for Stan-
dardization in Hematology published guidelines regarding the mon-
itoring of oral anticoagulants; it recommended the use of INR to report
PT results [14]; the indices of INR and PT were correlated. INR is cal-
culated from PT and the international sensitivity index (ISI) of mea-
suring reagent. INR = (patient PT/normal control PT) ISI. Our study
showed that the RIs established for INR and PT were consistent; this
verified the correlation between PT and INR. The age partitions de-
termined for APTT, TT, and FIB were different from those determined
for PT. The RI of APTT in the 1 month to 1 year age group was wider
than that of the 1–12-year age group, with more extreme upper and
lower limits; overall, the RI for the 1–12-year age group shifted
downward compared to that of adults [7]. In this study, the trend of the
APTT level was consistent with that of the study by Toulon in France
[5], which also used the ACL Top 700 system. However, the overall
APTT level of the Chinese population was longer than that of the French
population, irrespective of whether they were adults or children; this
may be due to racial differences. Kanaji et al. and Endler et al. showed
that the allele frequency of the frequently occurring C → T poly-
morphism in the factor XII promoter region at nucleotide 46 was higher
in Orientals than in Caucasians and Europeans [15,16]. This led to
lower plasma factor XII activity in Orientals; this may explain the
prolongation of APTT in Chinese populations [17]. The pattern of TT
values and RIs established were similar to those for APTT, and the RI of
TT in childhood was wider than that of adults (16–18 s) [7]. TT was
considered abnormal if exceeded that of the normal control in a clinical
setting by at least 3 s. If no separate RIs of TT are established in
childhood, some TT test results may be misjudged, particularly during
infancy. Human plasma fibrinogen is synthesized in the liver [18]. The
overall level of FIB in the 1 month to 1-year age group was lower than
that in the 1–12-year age group, and the RIs of both were lower than
those of adults [7]. This may be explained by the fact that FIB synthesis
is lower during childhood. Compared with the Austrian cohort studied
by Weidhofer et al. [6], the RIs of FIB in this Chinese population were
narrower, showing a lower upper limit; this difference may be attri-
butable to different detection instruments and reagents, or ethnic dif-
ferences.
In summary, our study has established RIs of PT, INR, APTT, TT, and
FIB for children in southwest Fujian, China, and is the first of its kind to
be performed in this region. The obtained data confirmed that the RIs of
PT, INR, APTT, TT, and FIB for children (from 1 month to 12 years)
differed from the RIs defined for adults. In this study, the RIs of coa-
gulation indices also differed across various age groups among children.
Our study has a limitation; the sample sizes of the neonatal and ado-
lescent age groups were relatively small. Therefore, the corresponding
RIs could not be established. Differences caused by race, age, and sex
and differences in methodology, detection systems, and reagents may
affect the applicability of selected RIs. We recommend that laboratories
capable of investigating coagulation function should establish RIs sui-
table for themselves. Laboratories that cannot establish their own RIs
should select those that have been established by other laboratories in
their own conditions, and quote this after verification.
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Table 3
Age-specific reference intervals for five coagulation indices.
Indices Reference interval
Age range (y,m,d) Samples, n Median Lower limit Upper limit Lower 90% CI Upper 90% CI
PT, sec ≥29 d–<3 y 1022 11.29 10.00 12.67 9.93–10.07 12.60–12.74
≥3 y–<12 y 710 11.75 10.60 13.10 10.40–10.70 13.02–13.12
INR ≥29 d–<3 y 1021 1.05 0.93 1.17 0.92–0.93 1.16–1.18
≥3 y–<12 y 709 1.09 0.98 1.21 0.97–0.99 1.20–1.22
APTT, sec ≥29 d–<1 y 406 35.69 27.43 43.68 26.84–28.21 42.87–44.67
≥1 y–<12 y 1320 34.15 27.87 40.80 27.44–28.07 40.34–41.18
TT, sec ≥29 d–<1 y 404 18.12 15.40 21.27 15.16–15.61 21.11–21.41
≥1 y–<12 y 1326 16.60 14.42 18.90 14.30–14.50 18.80–19.00
FIB, g/L ≥29 d–<1 y 399 1.99 1.34 2.94 1.29–1.40 2.86–3.06
≥1 y–<12 y 1312 2.42 1.73 3.36 1.70–1.75 3.33–3.39
Note: y, year; m, month; d, day; n, the net sample number; ≥29 d–<1 y, infants; ≥1 y– 3 y, toddlers; ≥3 y–<6 y, preschool-age children; ≥6 y–<12 y, school-
age children.
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